Evidence map›Paper›PMID 42486817›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026

[Butyrate alleviates

Minyu Dong, Zeyang Fang, Yunyun Zhang, Youliang Wu, Huangjie Zheng, Yongjun Liu, Qiong Yang, Deqian Kong, Kequan Chen, Siqi Wang

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Minyu DongDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Zeyang FangDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Yunyun ZhangDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Youliang WuDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Huangjie ZhengDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Yongjun LiuDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Qiong YangDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Deqian KongDepartment of Gastroenterology, Yangchun People's Hospital, Yangjiang 529600, China.
Kequan ChenDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Siqi WangDepartment of Gastroenterology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.

Funding

Natural Science Foundation for the Youth (NSFY) of China 82500630
6 · The paper itself

Abstract

objectivesTo investigate the mechanism by which obesity exacerbates

methodsIn mouse models of high-fat diet (HFD)-induced obesity and CDI and normal diet-fed mouse models of CDI, the effect of butyrate treatment on hepatic lipid deposition and liver function was assessed using Oil Red O staining and by measuring aspartate aminotransferase and alanine aminotransferase levels. Superoxide dismutase (SOD) activity and malondialdehyde (MDA) of the mice were determined, and colonic injury was evaluated using HE staining. The expression levels of intestinal mucosal barrier proteins ZO-1 and occludin were detected by RT-PCR and immunohistochemistry, and the levels of

resultsCompared with normal diet-fed mice, the HFD-fed mice with CDI had a significantly higher mortality rate and exhibited severer colonic damage, intestinal barrier function impairment and liver injury with significantly reduced fecal SCFAs concentrations. Butyrate replacement therapy markedly alleviated CDI symptoms, improved intestinal barrier function, and reduced the levels of liver injury markers. Fecal microbiota transplantation produced similar effects to butyrate and obviously alleviated CDI symptoms and increased fecal SCFAs concentrations in the mouse models.

conclusionsHFD significantly exacerbates the progression of CDI in mice, and butyrate shows the potential as an alternative therapy for improving obesity-associated CDI.

Indexed as

ButyratesClostridium InfectionsObesityAnimalsClostridioides difficileDiet, High-FatDisease Models, AnimalGastrointestinal MicrobiomeHumansMaleMiceMice, Inbred C57BLMice, ObeseZonula Occludens-1 ProteinButyratesTjp1 protein, mouseZonula Occludens-1 ProteinbutyrateClostridium difficile infectionfecal microbiota transplantationintestinal barrierobesity

Identifiers

PMID42486817
PMCPMC13391531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.